SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980; 1: 33940.
  • 2
    Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A. Prevention of neural-tube defects with folic acid in China. China–U.S. collaborative project for neural tube defect prevention. N Engl J Med 1999; 341: 148590.
  • 3
    Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 160814.
  • 4
    Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153: 9618.
  • 5
    Meijer WM, De Walle HE, Kerstjens-Frederikse WS, De Jong-van den Berg LT. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol 2005; 20: 2037.
  • 6
    Central Bureau of Statistics, State of Israel. Statistical Abstract of Israel 2008, No. 59. Available at http://www.cbs.gov.il/ts/ (last accessed 16 March 2009).
  • 7
    Central Bureau of Statistics, State of Israel. Hoda’a laitonut (in Hebrew). Available at http//www.cbs.gov.il/reader/newhodaot/searh_text_hodaot.html (last accessed 25 November 2008).
  • 8
    Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30: 14555.
  • 9
    Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program, 2009. Available at http://www.cdc.gov/ncbddd/bd/macdp.htm (last accessed 12 March 2009).
  • 10
    Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA; National Birth Defects Prevention Study. Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A Clin Mol Teratol 2003; 67: 193201.
  • 11
    Correa-Villasenor A, Cragan J, Kucik J, O’Leary L, Siffel C, Williams L. The metropolitan Atlanta congenital defects program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol 2003; 67: 61724.
  • 12
    Sheiner E, Shoham-Vardi I, Sheiner EK, Mazor M, Katz M, Carmi R. Maternal factors associated with severity of birth defects. Int J Gynaecol Obstet 1999; 64: 22732.
  • 13
    Sheiner E, Shoham-Vardi I, Weitzman D, Gohar J, Carmi R. Decisions regarding pregnancy termination among Bedouin couples referred to third level ultrasound clinic. Eur J Obstet Gynecol Reprod Biol 1998; 76: 1416.
  • 14
    Stoltenberg C, Magnus P, Lie RT, Daltveit AK, Irgens LM. Birth defects and parental consanguinity in Norway. Am J Epidemiol 1997; 145: 43948.
  • 15
    Zlotogora J. Genetic disorders among Palestinian Arabs: 1. Effects of consanguinity. Am J Med Genet 1997; 68: 4725.
  • 16
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population based case–control study. Reprod Toxicol 2001; 15: 63746.
  • 17
    Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009; 360: 252835.
  • 18
    Meyerovitch J, Sherf M, Antebi F, Barhoum-Noufi M, Horev Z, Jaber L, Weiss D, Koren A. The incidence of anemia in an Israeli population: a population analysis for anemia in 34,512 Israeli infants aged 9–18 months. Pediatrics 2006; 118: e105560.
  • 19
    Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 83749.
  • 20
    De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology 1999; 60: 336.
  • 21
    Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 1996; 62: 17983.
  • 22
    Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. Epidemiology 1995; 6: 2128.
  • 23
    Einarson A, Shuhaiber S, Koren G. Effects of antibacterials on the unborn child: what is known and how should this influence prescribing. Paediatr Drugs 2001; 3: 80316.
  • 24
    Ben David S, Einarson T, Ben David Y, Nulman I, Pastuszak A, Koren G. The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis. Fundam Clin Pharmacol 1995; 9: 5037.
  • 25
    Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes. Epilepsia 2009; 50: 123746.
  • 26
    Greenshpoon L. Association between levels of folic acid in blood of pregnant Jewish and Bedouin women, and reported adherence with currently recommended supplementations. MPH Thesis. Department of Epidemiology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel, January 24, 2008.